Growth Metrics

Akari Therapeutics (AKTX) Capital Expenditures (2016 - 2017)

Akari Therapeutics recorded quarterly Capital Expenditures of $73770.0 in Q4 2017, up 335.95% quarter-over-quarter from -$31265.0 in Q2 2017, and down 28.19% year-over-year from $102730.0 in Q4 2016.

Akari Therapeutics' Capital Expenditures history runs 2 years deep, the most recent figure standing at $73770.0 for Q4 2017.

  • In Q4 2017, Capital Expenditures fell 28.19% year-over-year to $73770.0; the TTM figure through Dec 2017 stood at $36885.0 (down 32.63% YoY), while the FY2017 annual figure was $36885.0, down 32.63% from the prior year.
  • Capital Expenditures came in at $73770.0 for Q4 2017 at Akari Therapeutics, up from -$31265.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $102730.0 in Q4 2016 to a low of -$42083.0 in Q1 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 21.83 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - 786,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 73,770.00
Dec 31, 2017 73,770.00
Jun 30, 2017 -31,265.00
Jun 30, 2017 -31,265.00
Mar 31, 2017 -5,620.00
Mar 31, 2017 -5,620.00
Dec 31, 2016 102,730.00
Dec 31, 2016 102,730.00
Jun 30, 2016 -5,897.00
Jun 30, 2016 -5,897.00
Mar 31, 2016 -42,083.00
Mar 31, 2016 -42,083.00